Australia markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.38-0.26 (-4.61%)
At close: 04:00PM EDT
5.30 -0.08 (-1.49%)
After hours: 04:34PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.64
Open5.53
Bid5.38 x 200
Ask5.40 x 600
Day's range5.32 - 5.74
52-week range1.63 - 8.83
Volume2,776,305
Avg. volume2,833,243
Market cap612.153M
Beta (5Y monthly)1.68
PE ratio (TTM)N/A
EPS (TTM)-1.64
Earnings date01 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.80
  • Zacks

    Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

    Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.

  • GlobeNewswire

    Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

    SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 2:15 PM ET. A live webcast

  • GlobeNewswire

    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on April 1, 2024 the Company granted restricted stock units (RSUs) representing 6,400 shares of its common stock to one newly-hired non-executive employee. The grant was approved